ÂÜÀòÂÒÂ×

Peter Hallock is a director, editing and discovery at Verve Therapeutics. He has over 10 years of drug development experience in the biotechnology industry. Prior to joining Verve, he worked as the director of hematology and in-vivo delivery at Crispr Therapeutics, where he led multiple pre-clinical gene editing programs. He received his Ph.D. from NYU, in developmental genetics, where he elucidated the signaling pathways that regulate the formation and maintenance of mammalian neuromuscular synapses and how those pathways are perturbed in humans diagnosed with Dok-7 congenital myasthenic syndromes.